TEST:

Parsortix Liquid Biopsy

P=N/A, N=30, Completed, Institute of Oncology Ljubljana

P=N/A, N=130, Recruiting, Institute of Oncology Ljubljana

P=N/A, N=120, Completed, Centre Hospitalier Universitaire de Nīmes | Recruiting --> Completed

P=N/A, N=27, Completed, Institut Claudius Regaud | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Sep 2025 --> Jan 2026

These results support the clinical utility of HER2 assessment on CTCs with both workflows and highlight the potential diagnostic value of label-free CTC enrichment combined with HER2 quantification. Further studies in larger cohorts should be conducted to validate our findings and investigate the clinical relevance of HER2-positive CTCs detected with the developed pipeline, particularly in the context of anti-HER2 therapies.

This is the first report of a nuclear antigen-based method for isolating single CTCs in suspension, overcoming the limitations of membrane and cytokeratin markers commonly used in other solid tumors. By exploiting the large nuclear size of CTCs, this strategy provides an alternative and more standardized approach for single-cell isolation in tumors lacking specific surface markers.

The proposed model achieved an F1-score of 0.798, demonstrating its capability to distinguish CTCs from leukocytes. These findings highlight the potential of DL in refining CTC analysis and advancing liquid biopsy applications.

Notably, the brightfield imaging strategy eliminates the need for fluorescence microscopy, enabling cost-effective and rapid CTC detection. Together, these results validate the platform's clinical applicability for low-abundance CTC detection and highlight its potential for real-world liquid biopsy-based cancer monitoring.

Peripheral CTCs isolated from patients with HGSC were predictors of a poor prognosis. The ovarian vein was found to be a rich source of disseminating CTC clusters in HGSC. Further studies are warranted to investigate the utility of CTCs as markers of neoadjuvant chemotherapy response as well as for longitudinal monitoring. Molecular analysis of CTCs in HGSCs reveals a potential role of the immune system in CTC-mediated haematogenous metastasis.

"ANGLE plc...is delighted to announce that it has entered a collaboration with Myriad Genetics, Inc...Under the terms of the agreement, blood samples from cancer patients will be processed by ANGLE's research and development team utilising the Parsortix® system for the capture and harvest of intact cancer cells for downstream molecular analysis. Results for this analysis will compare CTC-DNA with matched patient tissue samples using Myriad Genetics' existing tissue-based assay."

P=N/A, N=36, Recruiting, Institut Claudius Regaud | Not yet recruiting --> Recruiting | Trial completion date: Jan 2026 --> May 2026 | Initiation date: Apr 2025 --> Aug 2025 | Trial primary completion date: Jan 2026 --> May 2026

P=N/A, N=450, Recruiting, Institut Claudius Regaud | Not yet recruiting --> Recruiting